Table 1.
Demographic and histological characteristics of women with breast cancer.
| No Bone Metastasis n = 208 | Bone Metastasis n = 53 | Statistics | |||
|---|---|---|---|---|---|
| Mean or n (%) | Range | Mean or n (%) | Range | p | |
| Age (years) | 57.0 | 28–89 | 55.9 | 33–84 | 0.49 |
| Premenopausal | 78 (37.5%) | 21 (39.6%) | 0.95 | ||
| Postmenopausal | 127 (61.1%) | 32 (60.4%) | |||
| UK menopausal status | 3 (1.4%) | 0 | |||
| HRT | 33 (25.9%) | 7 (21.9%) | 1 | ||
| BMI (Kg/m2) | 25.2 | 16–40 | 25.5 | 13–41 | 0.78 |
| Histological size (mm) | 26.6 | 3–210 | 29.3 | 5–70 | 0.35 |
| Molecular phenotype | 0.45 | ||||
| Luminal A | 67 (32.7%) | 21 (39.6%) | |||
| Luminal B | 56 (27.3%) | 16 (30.3%) | |||
| Triple negative | 51 (24.9%) | 12 (22.6%) | |||
| HER2 | 31 (15.1%) | 4 (7.5%) | |||
| Grade | 0.01 | ||||
| -Grade 1 | 23 (11.0%) | 0 (0%) | |||
| -Grade 2 | 88 (42.3%) | 30 (56.6%) | |||
| -Grade 3 | 95 (45.7%) | 21 (39.6%) | |||
| -Unknown | 2 (1%) | 2 (3.8%) | |||
| Lymphovascular invasion | 58 (27.9%) | 16 (30.2%) | 0.53 | ||
| Axillary positive LN | 81 (38.9%) | 29 (54.7%) | 0.01 | ||
| Multifocality | 52 (25%) | 8 (15.1%) | 0.19 | ||
HRT: hormone replacement therapy; BMI: body mass index; LN: lymph node; HER2: Human epidermal growth factor receptor 2, UK: unknown.